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Abstract
Background: Antipsychotic treatment has been repeatedly found to be associated with an increased risk for
venous thromboembolism in schizophrenia. The extent to which the propensity for venous thromboembolism is
linked to antipsychotic medication alone or psychosis itself is unclear. The objective of this study was to determine
whether markers of thrombogenesis are increased in psychotic patients who have not yet been treated with
antipsychotic medication.
Methods: We investigated the plasma levels of markers indicating activation of coagulation (D-dimers and Factor
VIII) and platelets (soluble P-selectin, sP-selectin) in an antipsychotic-naive group of fourteen men and eleven
women with acute psychosis (age 29.1 ± 8.3 years, body mass index 23.6 ± 4.7), and twenty-five healthy volunteers
were matched for age, gender and body mass index.
Results: D-dimers (median 0.38 versus 0.19 mg/l, mean 1.12 ± 2.38 versus 0.28 ± 0.3 mg/l; P = 0.003) and sP-
selectin (median 204.1 versus 112.4 ng/ml, mean 209.9 ± 124 versus 124.1 ± 32; P = 0.0005) plasma levels were
significantly increased in the group of patients with acute psychosis as compared with healthy volunteers. We
found a trend (median 148% versus 110%, mean 160 ± 72.5 versus 123 ± 62.5; P = 0.062) of increased plasma
levels of factor VIII in psychotic patients as compared with healthy volunteers.
Conclusions: The results suggest that at least a part of venous thromboembolic events in patients with acute
psychosis may be induced by pathogenic mechanisms related to psychosis rather than by antipsychotic treatment.
Finding an exact cause for venous thromboembolism in psychotic patients is necessary for its effective treatment
and prevention.
Background
Schizophrenia is a chronic mental disorder that affects
about 1% of people worldwide. The disease tends to
b e g i nw h e np a t i e n t sa r ey o u n ga n dr e s u l t si nas h o r -
tened life span. Indeed, the life span among patients
with schizophrenia is 20% shorter than that of the gen-
eral population (61 versus 76 years, on average).
Approximately 40% of mortality in schizophrenia is due
to “unnatural causes”, such as suicide or accidents.
Somatic disorders represent the remaining 60% of “nat-
ural causes” [1].
Patients with schizophrenia have higher rates of
somatic morbidity and mortality when compared with
the general population [2]. This is generally explained
by an unhealthy lifestyle, poor dietary habits, and the
use of antipsychotic medication [3]. Physical morbidity
and mortality in schizophrenia have recently been found
to be increasing [4-6].
The risk for cardiovascular mortality among those
with schizophrenia is increased twofold as compared
with patients without schizophrenia [3]. Of the modifi-
able risk factors, obesity, smoking, hypertension and
dyslipidemia are the most common [4].
Venous thromboembolism (VTE), which is clinically
manifest as a deep vein thrombosis (DVT) or a pulmon-
ary embolism (PE), is a multifactorial disease. The pri-
mary symptom of DVT is asymmetrical oedema of the
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cope or tachycardia are the most important signs for
pulmonary embolism [7]. The incidence of all types of
thrombosis are strongly dependent on age. Among indi-
viduals up to 40 years of age, venous thromboembolism
is the most common form of thrombosis. VTE is also
the most common cause of morbidity and mortality in
people under 40 years of age [8]. Risk factors for VTE
work in the sense of the Virchow’s triad: reduced blood
flow, changes in the vessel wall, and changes in blood
composition [9]. Most of the risk factors for thrombosis
fall in the first (stasis) and third (changes in blood coa-
gulability) group. The classification has recently changed
and includes genetic and acquired VTE risk factors [8].
Cardiovascular mortality, including death from VTE, has
recently become a topic of wide study among patients
with schizophrenia because the safety of the treatment
and the patient’s quality of life are considered more
i m p o r t a n tt h a ni nt h ep a s t[ 1 0]. Clinically, it is impor-
tant that patients treated with antipsychotic medications
be treated for metabolic and cardiovascular disease and
that collaborations with primary care physicians, dia-
betes specialists, and cardiologists be established to facil-
itate appropriate medical care for these patients [11,12].
Antipsychotic medication is associated with an
increased risk for VTE [13]. This has been specifically
s h o w ni nt h el o w - p o t e n tf i r s tg eneration antipsychotics
or clozapine [14-18]. There has also been increasing evi-
dence concerning the relationship between second gen-
eration antipsychotics (olanzapine, risperidone) and VTE
[19-23]. On the other hand, schizophrenia or bipolar
affective disorder themselves are associated with VTE
due to the increased prevalence of a sedentary lifestyle
and lack of movements in this population. Obesity, seda-
tion, hyperprolactinemia [24] or acute epinephrine secre-
tion [25] are all factors that increase the likelihood of
forming blood clots and are other important VTE risk
factors seen in patients with acute psychosis. The risk of
VTE is specifically increased in patients who are hospita-
lised or in physical restraints. The role of antipsychotic
medications versus the presence of the mental disorder
itself in the aetiology of VTE has not been fully clarified
in patients with schizophrenia or other psychoses [26].
The primary aim of the study was to determine
whether markers of thrombogenesis (D-dimers, blood
factor VIII) and thrombocyte activation (sP-selectin)
were activated in unmedicated patients with acute psy-
chosis as compared with matched healthy volunteers.
Methods
Subjects
The patients were recruited for the study at the Dept. of
Psychiatry, University Hospital in Hradec Králové. Inclu-
sion criteria were as follows: hospitalised patients with
acute psychosis (schizophrenia F20, delusional disorder
F22, acute schizophreniform psychosis F23.2 according
to the ICD-10 classification [27]), age between 18-55
years, unmedicated with antipsychotics, without serious
medical comorbidities or a history of VTE. We excluded
patients with pre-existing cardiovascular, pulmonary or
neurological disease by reviewing the patients’ medical
records. We also conducted a comprehensive physical
and laboratory check-up. This was supplemented by
obtaining the patients’ family history.
Healthy volunteers were recruited from the staff at the
University Hospital in Hradec Králové. Healthy volun-
teers without any mental or serious somatic disorder
were matched to the sample with respect to age, gender,
weight, and body mass index (BMI). The possibility of
mental illness among the volunteers was excluded by
using a psychiatric examination. All participants volun-
tarily signed the “informed consent” form.
Laboratory examinations
Venous blood from both the patients and healthy volun-
teers was taken between 7 and 9 AM after twelve hours
of fasting. Laboratory examinations for markers of
thrombogenesis and platelet activation are described in
Table 1.
Statistical analysis
We compared values of descriptive statistics (age, gen-
der, weight, body mass index) between the patients and
healthy controls using the Student’s t-test. As for labora-
tory assessments in patients versus healthy volunteers,
we used the Mann-Whitney U Test and Student’s t-test.
Ethical aspects
All aspects of the present study were approved by the
Ethical Committee of the University Hospital in Hradec
Králové. Even if patients signed the written “Informed
Consent” in a state of acute psychosis, all also agreed to
continue in the study in remission later on.
Results
Twenty-five (women N = 11) patients with acute psy-
chosis (schizophrenia N = 19; acute schizophreniform
Table 1 Laboratory examinations
Marker Method
D-dimers STA LIA-test® D-DI (Diagnostica Stago)
Normal values: <0.5 mg/l
Factor VIII DG-F VIII (Grifols)
APTT (C.K. PREST, Diagnostica Stago)
Normal values: 50-150% of the factor activity
sP-selectin ELISA method (R&D Systems)
Normal values: 82 ± 31 ng/ml
APTT - activated partial thromboplastin time; ELISA - enzyme-linked
immunosorbent assay; LIA - isoturbidimetric method
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included in the study. The control subjects were matched
to the patients with respect to age, gender, weight, and
body mass index. We did not find any significant demo-
g r a p h i cd i f f e r e n c eb e t w e e nt h ep a t i e n t sa n dh e a l t h y
volunteers (P = NS; Student’s t-test). Demographic data
on patients and healthy volunteers are shown in Table 2.
Plasma levels of D-dimer and sP-selectin were signifi-
cantly higher in the patients as compared with the
healthy volunteers (U = 157,000; p = 0.003 and U =
133,000; p = 0.0005, respectively; Mann-Whitney U
Test). The plasma level of D-dimer was pathologically
increased (> 0.5 mg/l) in ten patients and in only two
healthy controls. We found a trend (t = 1,911; df = 46;
p = 0,062; Student’s T-test) towards increased levels of
factor VIII in patients with psychosis as compared with
healthy volunteers. Laboratory data in patients and
healthy volunteers are presented in Table 3.
Discussion
Venous thromboembolism may not always be ade-
quately recognised in people with a severe mental disor-
der. Asymptomatic VTE, decreased interest in the
maintenance of good health care by either patients or
their physicians, a lack of collaboration between the
patient and his physicians, the patient’s distrust of other
medical specialists who are not psychiatrists, and finally
psychiatrists’ limited knowledge concerning VTE diag-
nostics are factors that may contribute to the underdiag-
nosis of VTE in patients with mental illness. At the
same time, the life of the patient may be at risk, espe-
cially in the case of pulmonary embolism [28].
Data in the literature concerning markers of thrombo-
genesis in unmedicated schizophrenic patients is limited.
Iwata et al. [29] found increased levels of serum soluble
L-selectin, but not sP-selectin, in 23 unmedicated
patients with schizophrenia when compared with
patients with major depression (N = 17; P = 0.02) or
healthy subjects (N = 36; P = 0.005).
In a study by Walsh et al. [30], patients with schizo-
phrenia (N = 19) had increased platelet expression of
surface receptors alpha(IIb) beta(IIIa) as compared with
healthy controls (N = 19; P < 0.0001), which may contri-
bute to their increased risk for cardiovascular illness.
Morioka et al. [31] reported the cases of two patients
(women who were 29 and 67 years of age, respectively)
with psychiatric stupor who developed venous thrombo-
sis. While dehydration, infection and decubitus ulcers
are serious physical complications of psychiatric stupor,
this condition also increases the risk of deep venous
thrombosis.
Our findings suggest that acute psychosis may reflect
a pro-coagulatory state. D-dimers are fragments of inso-
luble fibrin detectable in plasma after fibrin coagulum
has been cleaved by plasmin. Increased plasma level of
D-dimer results from pathological activation of blood
clotting and occurs following fibrinolysis. Assessment of
the D-dimer plasma level is important in clinical prac-
tice to exclude the diagnosis of deep vein thrombosis or
pulmonary embolism, especially in the outpatient setting
[32]. The specificity of D-dimers for the assessment of
VTE is limited due to the fact that increased plasma
levels can also be found in various kinds of inflamma-
tion, necrosis, tumours or infections. Nevertheless, we
did not find any clinical or laboratory markers of infec-
tion in our sample of patients. The increased plasma
l e v e lo fD - d i m e ri na c u t ep s y c h o s i sm a yb eam a r k e ro f
fibrinolysis in the course of pathological blood clotting,
when elevated epinephrine secretion stimulates the acti-
vation of thrombocytes [25,33]. Andreescu et al. [34]
described D-dimer as a risk factor for deep vein throm-
bosis in the Leiden Thrombophilia Study. The authors
studied the association of D-dimer with the risk of deep
vein thrombosis in 474 patients who were more than six
m o n t h so u tf r o mt h ed i a g n o s i so faf i r s tD V Ta n di n
474 age- and sex-matched controls. For D-dimer levels
above the 70th percentile (130.5 ng/ml), the odds ratio
(OR) for DVT was 2.2 (95% CI 1.6-2.9).
The finding of elevated sP-selectin plasma levels as a
marker of inflammation and increased thrombogenesis
in our patients is consistent with the process described
above. Thrombocytes are involved in atherogenesis if
Table 2 Demographic data on patients and healthy volunteers
Patients (N = 25;
women N = 11)
Healthy volunteers (N = 25; women N = 12)
Average (SD) Median Range Average (SD) Median Range p-value
(T-test)
Age (years) 29.1 (8.3) 28 18-52 29.3 (8.3) 28 19-53 NS
Weight (kg) 69.5 (14.7) 70 39-102 72.4 (12.7) 67 55-101 NS
BMI 23.6 (4.7) 23 16.2-39.8 23.5 (2.6) 23.5 19.3-29.6 NS
Duration of
untreated
psychosis (months)
12.3 (18.4) 1.3 0.25-60 - - - -
BMI - Body Mass Index, NS - non-significant, SD - standard deviation. T-test - Student’s t-test
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pro-coagulatory protein sP-selectin is produced by acti-
vated thrombocytes [35]. sP-selectin induces migration
and adhesion of leukocytes as well as stimulation of
endothelial cells and thrombocytes. sP-selectin plays an
important role as a connecting element between inflam-
mation and thrombosis [36]. Not only have increased
plasma levels of sP-selectin been found in patients with
venous thromboembolism in a short time after the acute
incident [37,38], but they were also present after several
months [39].
The median level of factor VIII coagulatory activity
showed a trend towards being higher in patients than in
healthy volunteers (median 148 versus 110%; U =
216,500; P = 0.062). The difference was statistically sig-
nificant in the subgroups of women (psychotic versus
healthy women; median 170 versus 111%; U = 33,000;
p = 0.042). Twelve patients in contrast to six healthy
volunteers had factor VIII coagulatory activity that was
abnormally high (above 150%). Increased blood levels of
factors II, V, and VIII are associated with an increased
risk of venous thromboembolism according to the cur-
rent literature [40]. Individuals with factor VIII coagula-
tory activity above 150 IU/dl have a threefold risk of
developing VTE as compared with subjects with activity
<150 IU/dl; and they are six times more likely
to develop this condition than people with activity
<100 IU/dl. People with factor VIII coagulatory activity
equal to 150 IU/dl are at a 2.7-fold increased risk of
venous thromboembolism when compared with the gen-
eral population [41].
The authors are aware of limitations of the results.
The study sample is small, so the results may only be
considered as preliminary at this moment. The generali-
sibility of the findings may also be limited by the disease
heterogeneity in psychosis.
Conclusions
Since the 1950s, when the first antipsychotic medica-
tions were developed, there have been reports of an
increased prevalence of venous thromboembolism in
patients treated with antipsychotics. In the last decade,
this topic has received increased attention within the
scientific literature. The diagnoses of schizophrenia or
bipolar affective disorder themselves as well as hospitali-
sation or stress-induced increases in sympathetic activa-
tion and catecholamine blood levels are also pro-
thrombogenic factors. In our sample of unmedicated
patients with acute psychosis, we found an increased
level of blood markers of the pathological activation of
blood clotting and fibrinolysis, as well as activation of
thrombocytes when compared with matched healthy
volunteers. Prospective studies are needed to elucidate
the biological mechanisms involved in the relationship
between venous thromboembolism and antipsychotic
medication versus the mental disorder itself.
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